These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 25989277)
1. Comment on: 'evaluation of chemoresponse assays as predictive markers'. Tian C; Gabrin MJ; Brower SL; Sargent DJ Br J Cancer; 2015 Jun; 112(12):1977-8. PubMed ID: 25989277 [No Abstract] [Full Text] [Related]
2. Response to comment on: 'evaluation of chemoresponse assays as predictive biomarkers'. Korn EL; Freidlin B Br J Cancer; 2015 Jun; 112(12):1978. PubMed ID: 25965166 [No Abstract] [Full Text] [Related]
3. Evaluation of chemoresponse assays as predictive markers. Korn EL; Freidlin B Br J Cancer; 2015 Feb; 112(4):621-3. PubMed ID: 25584494 [TBL] [Abstract][Full Text] [Related]
4. Advances and challenges in the use of biomarkers in clinical trials. Chabner B Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440 [No Abstract] [Full Text] [Related]
5. Now's the time to find biomarkers on purpose. Auman JT; McLeod HL Ann Oncol; 2010 Feb; 21(2):193-194. PubMed ID: 20047974 [No Abstract] [Full Text] [Related]
6. Advances in biomarkers for targeted agents. Maitland ML Clin Adv Hematol Oncol; 2011 Sep; 9(9):688-90. PubMed ID: 22402514 [No Abstract] [Full Text] [Related]
7. The search for optimal response prediction in cancer leads to a personalized approach. Van Cutsem E; Ciardiello F Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283 [No Abstract] [Full Text] [Related]
9. Systems biology makes it personal. Brynildsen MP; Collins JJ Mol Cell; 2009 Apr; 34(2):137-8. PubMed ID: 19394290 [TBL] [Abstract][Full Text] [Related]
10. The epothilones: translating from the laboratory to the clinic. Lee JJ; Swain SM Clin Cancer Res; 2008 Mar; 14(6):1618-24. PubMed ID: 18347162 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277 [TBL] [Abstract][Full Text] [Related]
12. Validation of analytic methods for biomarkers used in drug development. Chau CH; Rixe O; McLeod H; Figg WD Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475 [TBL] [Abstract][Full Text] [Related]
13. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Paik S Biotechnol Annu Rev; 2003; 9():259-67. PubMed ID: 14650930 [TBL] [Abstract][Full Text] [Related]
14. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955 [TBL] [Abstract][Full Text] [Related]
17. Qualification of imaging biomarkers for oncology drug development. Waterton JC; Pylkkanen L Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478 [TBL] [Abstract][Full Text] [Related]
18. Markers for efficacy of mammalian target of rapamycin inhibitor. Liao YM; Sy A; Yen Y Anticancer Res; 2012 Oct; 32(10):4235-44. PubMed ID: 23060543 [TBL] [Abstract][Full Text] [Related]
19. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA. Scholler N IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459 [No Abstract] [Full Text] [Related]
20. [Are expression signatures worthless?]. Jordan B Med Sci (Paris); 2012 May; 28(5):547-50. PubMed ID: 22643011 [No Abstract] [Full Text] [Related] [Next] [New Search]